| 37th week of 2008 patent applcation highlights (09-11-08/09-11-08_49) part 49 |
| Patent application number | Title | Published |
|---|
| 20080221002 | Dispersant - A novel ashless polymeric dispersant is claimed which is suitable for use in an automotive lubricant composition. The ashless polymeric dispersant has a number average molecular weight of between 200 and 15,000 and derived from the reaction of a polar head group, which comprises a polar moiety having more than one amine, alcohol, acid or halogen functionality with two or more polar tail groups where each polar tail group comprises a polymeric backbone of 2 to 30 monomeric repeat units, each repeat unit comprising a hydrocarbon chain functionalised by the presence of at least one electronegative element or moiety. The dispersant has good dispersancy properties, when used as a sole dispersant or in combination with other dispersants. It provides enhanced seal resistance and has good oxidative stability in automotive applications as compared to current commercial products. Furthermore the low temperature viscosity of an automotive lubricant composition containing the dispersant is superior to that of a composition with current commercial dispersants. | 09-11-2008 |
| 20080221003 | CONSUMER PRODUCTS HAVING VARYING ODOR PATTERNS - Consumer products having fragrance that can develop distinguishable odor patterns which are separately detectable. Scent dynamics allow the consumer with one and the same product to experience different scent experiences during a single application. The limited range and monotony of odor associated with the conventional perfumed consumer products is thereby completely broken. | 09-11-2008 |
| 20080221004 | Cleaning Solution for a Semiconductor Wafer - A cleaning solution for a semiconductor wafer comprises ammonia, hydrogen peroxide, a complexing agent and a block copolymer surfactant diluted in water. The cleaning solution can be used in single wafer cleaning tools to remove both particulate contaminants and metallic residues. | 09-11-2008 |
| 20080221005 | Stable Bleaches With Coloring Agents - The invention provides an aqueous bleaching solution for substrate treatment comprising a source of oxidant and a suspended polymer matrix having a plurality of optically functional particles associated with one or more copolymers present in the polymer matrix. The plurality of optically functional particles are associated with the copolymer during polymerization of at least one hydrophobic and at least one hydrophilic monomer so as to form a polymer matrix useful to impart an aqueous bleaching solution with optically functional properties providing a benefit to the solutions during storage, use and application to substrates for treatment. In accordance with various embodiments of the invention, the suspended polymer matrix forms a substantially stable dispersion of the optically functional particles in the aqueous bleaching solution, and provides compositions, methods and kits for employing aqueous bleaching solutions having optically functional properties that are maintained over substantially long storage times. | 09-11-2008 |
| 20080221006 | Biodegradable alkaline disinfectant cleaner with analyzable surfactant - An aqueous, alkaline cleaning composition for use on hard-to-clean soils, encountered in pharmaceutical, personal care, food and cosmetic manufacturing, comprising a source of alkalinity, a biodegradable surfactant system further comprising one or more surfactants, one or more hydrotropes, and a UV-analyzable surfactant, and a biodegradable chelating agent. The composition offers unique advantages of stability over the expected shelf life, low-foaming property, phosphate-free and biodegradable components, and unexpectedly enhanced antimicrobial, including virucidal, activity in one cleaning composition. The UV-analyzable surfactant allows for validation of cleaning processes using known techniques for manufacturers who are required or desire to do so. | 09-11-2008 |
| 20080221007 | Aqueous Cleaning Compositions - An aqueous cleaning composition comprising:
| 09-11-2008 |
| 20080221008 | DETERGENT COMPOSITIONS AND THE USE OF ENZYME COMBINATIONS THEREIN - New detergent compositions and the use of enzyme combinations therein are disclosed. The compositions have enhanced stability of non protease enzymes present in the compositions. | 09-11-2008 |
| 20080221009 | Hydrophobic self-cleaning coating compositions - A super hydrophobic self cleaning coating composition that can be applied by conventional methods such as by spraying the composition onto a surface creating a wet and dry dirt repellent coating on the surface. The super hydrophobic self cleaning coatings are used on exterior automotive and boat surfaces, and in many other applications, to produce a self cleaning surface, reduce adherence of dirt and contaminants to a treated surface, and reduce drag in some applications providing an energy savings. The coating utilizes a blend of organic and/or inorganic polymers with hydrophobic nanoparticles of fumed silica and/or titania in a volatile solvent which evaporates at ambient temperature. The coating solves the problem of poor resistance to UV light, opaque appearance, and/or some abrasion resistance not found in previous coatings of similar nature. A preferred coating has good resistance to UV light and some resistance to abrasion. Clear, nearly transparent and translucent coatings are produced as compared to conventional coatings of comparable hydrophobicity which are typically white or opaque. The coating can be applied by a single and easy spraying method and the super hydrophobic property can be achieved by drying the film by evaporation of the solvent at ambient temperature for 5 to 10 minutes. Embodiments of the super hydrophobic self-cleaning coating composition result in a clear coating or in some cases a translucent dirt repellant film for coating on painted material, plastic, metal, glass, ceramic, fiberglass or a polymer substrate. The coating utilizes a blend of organic and/or inorganic polymers with hydrophobic nanoparticles of fumed silica and/or titania in a volatile solvent. At least one preferred coating composition comprising an effective amount of a treated fumed silica in a solvent resulting in a coated surface providing a contact angle of at least 165 degrees as compared to water having a contact angle of from 10 to 15 degrees on a noncoated surface. The composition imparts a degree of hydrophobicity to a surface so that the surface will have a tilt angle of sliding of less than 2 degrees as compared to water on a noncoated surface having a tilt angle of sliding of 90 degrees or higher. The coating composition is removed by washing with a detergent or applying pressure to the coating wiping same from the treated surface. Exposure to water in the form of rain or snow does not remove the coating composition. | 09-11-2008 |
| 20080221010 | Fabric Conditioning Compositions - An aqueous fabric softening composition comprising: (i) at least one cationic fabric softening compound and (ii) at least one oily sugar derivative which comprises at least 5% by weight of impurities selected from free fatty acid, fatty acid methyl ester, soap, inorganic salts and mixtures thereof. The composition comprising less than 0.5% by weight of fatty complexing agent. The compositions allow impure OSD's to be successfully employed. | 09-11-2008 |
| 20080221011 | Targeting complement factor H for treatment of diseases - The invention provides a CR2-FH molecule comprising a CR2 portion comprising CR2 protein or a fragment thereof and a FH portion comprising a factor H protein or a fragment thereof, and pharmaceutical compositions comprising a CR2-FH molecule. Also provided are methods of using the compositions for treatment diseases in which the alternative complement pathway is implicated, such as age-related macular degeneration, rheumatoid arthritis, and ischemia reperfusion. | 09-11-2008 |
| 20080221012 | Activatable Clostridial Toxins - Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids. | 09-11-2008 |
| 20080221013 | Neurobiological compositions - Disclosed herein are compositions and methods for the treatment or prevention of neurological disorders using lynx compounds. The invention further discloses compositions and methods for the modulation of acetylcholine receptor activity. | 09-11-2008 |
| 20080221014 | Method of Diagnosing and Treating Glioma - The present invention is directed to methods and compositions for the diagnosis, prognosis and treatment of glioma in mammals. | 09-11-2008 |
| 20080221015 | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS RELATED TO EPHRIN SIGNALING WITH CUPREDOXINS AND MUTANTS THEREOF - The present invention relates to compositions and methods of use of cupredoxins, and variants, derivatives and structural equivalents of cupredoxins that interfere with the ephrin signaling system in mammalian cells. Specifically, the invention relates to compositions and methods that use cupredoxins, such as azurin, rusticyanin and plastocyanin, and variants, derivatives and structural equivalents thereof, to treat cancer in mammals. The invention specifically includes mutants with altered Eph binding constants and selectivities. | 09-11-2008 |
| 20080221016 | CD25+ DIFFERENTIAL MARKERS AND USES THEREOF - The present invention is directed to methods and compositions for the identification of novel targets for diagnosis, prognosis, therapeutic intervention and prevention of autoimmune disorders, transplant rejection and cancer. In particular, the present invention is directed to the identification of novel targets which are CD25 | 09-11-2008 |
| 20080221017 | Pharmaceutical or cosmetic composition and use of a PKC inhibitor with an MMP inhibitor for inhibiting langerhans cell migration - The invention concerns a pharmaceutical or cosmetic composition, characterized in that it comprises at least a compound for inhibiting Langerhans' cell migration, said active compound being selected in the group consisting of protein kinase C (PKC) inhibiting compounds, matrix metalloprotease (MMP) inhibiting compounds, and combinations thereof, and at least a pharmaceutically or cosmetically acceptable carrier. Said composition enables to inhibit considerably Langerhans' cell migration induced by the presence of an allergenic agent. | 09-11-2008 |
| 20080221018 | Crystalline solid and amorphous forms of (-)- halofenate and methods related thereto - The present invention provides crystalline solid and amorphous forms of (−)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (−)-halofenate. | 09-11-2008 |
| 20080221019 | Treatment of Inclusion Body Myositis - The present invention relates to the field of myopathy and particularly to the treatment and/or prevention of inclusion body myositis (IBM). A composition is provided, which comprises as an active ingredient either growth hormone, a secretagogue thereof or a mixture thereof, to cure IBM or suppress the symptoms associated therewith. | 09-11-2008 |
| 20080221020 | Dendrimers as Molecular Translocators - Transport molecules include a dendrimer and a biologically active molecule. The dendrimer of such transport molecules includes at least one guanidine group, at least one protonated guanidine group, at least one protected guanidine group, at least one amidine group, at least one protonated amidine group, at least one protected amidine group, at least one ureido group, at least one protonated ureido group, at least one protected ureido group, at least one thioureido group, at least one protonated thioureido group, or at least one protected thioureido group. The biologically active molecule is bonded to the dendrimer. A method of increasing the bioavailability of a drug includes bonding the drug to a dendrimer of the invention. | 09-11-2008 |
| 20080221021 | Novel Corticotropin-Releasing Factor Receptor 1 (Crfr1) Agonist - The present invention relates to a compound which is highly selective for CRFR1 without having any significant cross-reactivity for corticotropin-releasing-factor-receptor-2 (CRFR2) and/or corticotropin-releasing-factor-binding protein (CRFBP), said compound comprising or alternatively consisting of the amino acid sequence as depicted in SEQ ID No: 1. In another aspect, the present invention relates to a pharmaceutical and/or diagnostic composition comprising the novel CRFR1 agonist of the present invention. The present invention also provides a kit comprising the novel CRFR1 agonist of the present invention and optionally instructions to use. Furthermore, the present invention provides the use of the compound of the present invention for the preparation of a pharmaceutical composition for the treatment of depression and, additionally, the use of the compound of the present invention for the preparation of a diagnostic composition for the determination of pituitary corticotroph responsiveness and/or for differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushing's syndrome. | 09-11-2008 |
| 20080221022 | Prouroguanylin, and Synthetic Analogs or Proteolytic Cleavage Products Derived from It, as Therepeutic and Diagnostic Agents for Diseases Involving Salt and/or Fluid Homeostasis - A method for treating a disorder characterized by salt retention, fluid retention, and combinations thereof. A method for determining the presence of or the progression of a disorder characterized by salt retention, fluid retention, salt loss, fluid loss, and combinations thereof. An immunoassay kit for detecting a level of prouroguanylin in a sample. | 09-11-2008 |
| 20080221023 | Use of Protein Hydrolysates For the Manufacture of a Medicament For Prophylaxis and/or Treatment of a Dpp-IV Mediated Condition - Disclosed is the use of one or more protein hydrolysates for the manufacture of a medicament, food supplement, beverage or food product for prophylaxis and/or treatment of a DPP-IV mediated condition, like, for example, obesity, type II diabetes mellitus, autoimmune diseases. | 09-11-2008 |
| 20080221024 | Analogs of Shk Toxin and Their Uses in Selective Inhibittion of Kv1. 3 Potassium Channels - Analogs of ShK toxin and methods for using such ShK analogs. The ShK analogs generally comprise ShK toxin attached to a chemical entity (e.g. an atom, molecule, group, residue, compound, moiety, etc.) that has an anionic charge. In some embodiments the chemical entity attached to the ShK toxin may comprise an amino acid residue. The ShK analogs may be administered to human or non-human animal subjects to cause inhibition of potassium channels or to otherwise treat diseases or disorders. In some embodiments, the chemical entity to which the ShK toxin is attached may be chosen to provide selective inhibition of certain potassium channels (e.g., Kv1.3 channels) over other potassium channels (e.g., Kv1.1 channels). In come embodiments, the chemical entity to which the ShK toxin is attached may include a fluorophore, thereby providing a fluorophore tagged ShK analog. Such fluorophore tagged ShK analogs may be used in flow cytometry alone, or in conjunction with class II tetramers that can detect autoreactive cells. | 09-11-2008 |
| 20080221025 | Use of Trpc Channel for the Treatment of a Cardiovascular Disease - The invention refers to the use of a TRPC channel, an inactivating mutant thereof, or a nucleotide sequence coding for the TRPC channel or for the inactivating mutant for the production of a medicament for the treatment of a cardiovascular disease and a method of screening a modulator of the TRPC channel or an inactivating mutant thereof. | 09-11-2008 |
| 20080221026 | Process for manufacture of nematode-extracted anticoagulant protein (NAP) - The present invention provides a process for manufacture of purified Nematode-extracted Anticoagulant Proteins (NAPs), wherein the NAP manufactured by the claimed process method is a NAP drug substance that can be formulated as a NAP drug product. The present invention provides NAP drug substances and NAP drug products manufactured by the process disclosed herein. In one embodiment, the present invention provides a process for manufacture of rNAPc2/proline drug substance and rNAPc2/proline drug product, and provides rNAPc2/proline drug substance manufactured by the process disclosed herein. | 09-11-2008 |
| 20080221027 | Composition and Methods for the Treatment of Duchene Muscular Dystrophy - Patients are treated for muscular dystrophy by artificially increasing effective sarcospan activity in the patient's muscle tissue. Sarcospan (or fragments thereof) can be administered directly to the tissue, or their production can be induced by gene therapy. Modifications are also contemplated to be effective, including for example, a lipid, TAT or other tag. Also contemplated are compositions that include a protein, mRNA or gene stabilizer, degradation inhibitor, and/or oligomerization inhibitor. Increased presence of sarcospan can also be accomplished indirectly, using a vector having an entire sarcospan gene sequence, fragment or related construct, modulating a transcription factor, and so forth. | 09-11-2008 |
| 20080221028 | Compositions and Methods for Treating Atherosclerosis - Peptides and mimetics of selected domains of mammalian serum amyloid A isoform 2.1 (SAA2.1) and compounds and compositions thereof are provided that enhance the effect on macrophage cholesterol ester hydrolase activity and/or inhibit acyl CoA:cholesterol acyl transferase activity. Methods of using these compositions in the treatment and/or prevention of atherosclerosis as well as coronary heart disease and cardiovascular disease are also provided. | 09-11-2008 |
| 20080221029 | METHODS FOR TREATMENT OF THIOL-CONTAINING COMPOUND DEFICIENT CONDITIONS - Certain embodiments in the present invention provide for methods for therapy of lung diseases and other conditions such as infection are provided. In certain embodiments, the methods comprise one or more agents capable of increasing thiol-containing compound transport via a transporter system (i.e., ABC transporters such as MDR-1 or MRP-2) in cells. Other embodiments can include the use of agents to modulate transport of thiol-containing compounds from the cell such as thiocyanate. In certain embodiments, therapeutic methods involve the administration of such agents to a patient afflicted with an inflammatory condition or infection responsive to stimulation of thiol-containing compound transport. | 09-11-2008 |
| 20080221030 | Inhibition of Wet Type Age Related Macular Degeneration (Amd) by Adiponectin or Acrp 30 - The present invention provides new methods of treating wet type of age related macular degeneration by administering adiponectin (APN) or a functional fragment derived therefrom. One of the pathological complications of age related macular degeneration (AMD) is choroidal angiogenesis or choroidal neovascularization (CNV). The inventors discovered that the level of APN expression is significantly lower in the choroids of the laser-induced mouse model of choroidal angiogenesis or choroidal neovascularization (CNV) than that of the control mice and that administration of recombinant adiponectin (rAPN) or a peptide derived from the globular domain of the intact APN protein to the mouse model of CNV reduced the size of CNV significantly. These studies are the first to demonstrate the inhibitory effect of adiponectin on choroidal angiogenesis and thus provide the basis for treating a condition or disease involving angiogenesis, particularly age related macular degeneration, with administration of adiponectin. | 09-11-2008 |
| 20080221031 | Kallikrein Inhibitors and Anti-Thrombolytic Agents and Uses Thereof - Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia or a focal brain ischemia, e.g., in patients subjected to invasive surgical procedures, especially procedures requiring cardiopulmonary bypass. | 09-11-2008 |
| 20080221032 | Factor VIIa-Polysialic Acid Conjugate Having Prolonged In Vivo Half-Life - The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor VIIa (FVIIa) or biologically active derivatives thereof, which are bound to a carbohydrate moiety comprising 1-4 sialic acid units, wherein the in vivo half-life of the proteinaceous construct is substantially prolonged in the blood of a mammal, as compared to the in vivo half-life of a FVIIa molecule not bound to a carbohydrate moiety. The invention also provides a method for controlling bleeding in a mammal having a bleeding disorder due to functional defects or deficiencies of FVIIa, FVIII, or FIX. The invention also provides a method for controlling bleeding in a mammal during surgery or trauma. | 09-11-2008 |
| 20080221033 | Monitoring of Cardiac Natriuretic Peptides During Diagnosis, Management, and Treatment of Cardiac Diseases - In a cardiac monitoring method, at east an inactive natriuretic peptide ( | 09-11-2008 |
| 20080221034 | CANINE SPECIFIC GROWTH HORMONE RELEASING HORMONE - A composition and a method of increasing growth hormone (“GH”) values in a canine or dog, and more specifically, a canine- or dog-specific growth hormone releasing hormone (“dGHRH”), or functional biological equivalent thereof. The dGHRH is an isolated composition or a nucleic acid molecule that encodes the dGHRH or functional biological equivalent. Also, a method for delivering the composition of this invention to a subject, wherein the dGHRH increases the level of growth hormone (“GH”) secretion in a recipient subject, such as a canine or dog. | 09-11-2008 |
| 20080221035 | Ply-Gbs Mutant Lysins - Methods, compositions and articles of manufacture useful for the treatment of various Group B streptococci (GBS) bacteria using various lysins, including certain PlyGBS mutant lysins, are provided. | 09-11-2008 |
| 20080221036 | Use of AGT and its derivatives for manufacturing anti-angiogenesis pharmaceutical compositions - An object of the present invention is the use of at least one inhibitor of angiogenesis consisting of AGT or derivatives thereof in the manufacture of a drug for treating pathologies or disorders notably angiogenesis-dependent or mediated pathologies generally characterised by excessive angiogenesis. | 09-11-2008 |
| 20080221037 | Methods and compositions for treating disorders involving excitotoxicity - It is shown here that hedgehog polypeptides possess novel activities beyond phenotype specification. Using cultures derived from the embryonic day 14.5 (E14.5) rat ventral mesencephalon, we show that hedgehog is also trophic for dopaminergic neurons and other neurons which are sensitive to exotoxicity. | 09-11-2008 |
| 20080221038 | Compounds for Control of Appetite - This invention relates generally to peptides including tripeptides and to methods for pharmaceutical treatment of mammals using such tripeptides and analogs thereof. More specifically, the invention is directed to neuropeptide Y (“NPY”) receptor antagonists and agonists including O-glycosylated tripeptides, i.e. O-glycopeptides, and extended tripeptides, and their analogs, as well as to PYY analogs, to pharmaceutical compositions containing such tripeptides and PYY analogs, and to methods of treatment of mammals using such tripeptides and PYY analogs. In addition, the invention relates to methods of treatment of mammals using such tripeptides and PYY analogs for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm. | 09-11-2008 |
| 20080221039 | Kinin Antagonists For Treating Bladder Dysfunction - The present invention is related to the use of a kinin receptor antagonist for the manufacture of a medicament for the treatment and/or prevention of bladder dysfunction, whereby the kinin receptor is selected from the group comprising B1 and B2 receptors. | 09-11-2008 |
| 20080221040 | Compositions and Methods for the Control of Mammary Cell Number - The present invention provides new methods and uses of peptides in effecting a reduction in mammary cell number. The discovery that these peptides reduce mammary cell number further enables the use of these peptides in the treatment of cancer where the peptides can be used to reduce cell number and accordingly reduce or prevent tumour development. The inventor has further shown that the peptides have specific utility in the treatment of breast cancer. | 09-11-2008 |
| 20080221041 | Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension - The present invention relates to peptides which are highly biologically and pharmacologically active as therapeutic drug for the treatment of diseases related to hypertension, especially in medical interventions involving dilatation and remodeling of arterial blood vessels, either in the pulmonary or in the systemic circulation. The peptides which can be used according to the invention for the treatment of said diseases comprise at least one specific highly conservative amino acid residue sequence which seem to play an important role in connection with pulmonary and arteriolar hypertension events. It could be shown that the known naturally occurring peptides “vasoactive intestinal peptide (VIP)” and “pituitary adenylate cyclase-activating polypeptide (PACAP)”, having these specific sequences are potent drugs which can be successfully used for treatment of primary pulmonary hypertension (PPH), secondary pulmonary hypertension (SPH), and hypertension of the systemic circulation. Furthermore, the present invention discloses pharmaceutical compositions useful for treatment of PPH, SPH, and hypertension of the systemic circulation within said methods. | 09-11-2008 |
| 20080221042 | Alzheimer's disease-specific alterations of the ERK1/ERK2 Phosphorylation ratio-Alzheimer's disease-specific molecular biomarkers (ADSMB) - The present invention relates to methods of diagnosing Alzheimer's Disease as well as to methods of confirming the presence or absence of Alzheimer's Disease in a subject. The present invention is also directed to methods of identifying a lead compound useful for the treatment of Alzheimer's Disease by contacting non-Alzheimer's cells with an amyloid beta peptide, stimulating the cells with a protein kinase C activator, contacting the cells with a test compound, and determining the value of an Alzheimer's Disease-specific molecular biomarker. The present invention is also directed to methods of diagnosing Alzheimer's Disease in a subject by detecting alterations in the ratio of specific phosphorylated MAP kinase proteins in cells after stimulation with a protein kinase C activator. The Alzheimer's Disease-specific molecular biomarkers disclosed herein are useful for the diagnosis of Alzheimer's Disease, monitoring the progression of Alzheimer's Disease in a subject and in screening methods for the identification of compounds for treating or preventing Alzheimer's Disease. The invention is also directed to kits containing reagents for the detection and diagnosis of the presence or absence of Alzheimer's Disease using the Alzheimer's Disease-specific molecular biomarkers disclosed herein. | 09-11-2008 |
| 20080221043 | DENDRITIC MOLECULAR INTRACELLULAR TRANSPORTERS AND METHODS OF MAKING AND USING SAME - In accordance with the purpose(s) of the invention, as embodied and broadly described herein, the invention, in one aspect, relates to compounds comprising the structure: | 09-11-2008 |
| 20080221044 | Composition for Inhibiting the Onset of Arteriosclerosis and Inhibition Method - [Object] To provide a composition for inhibiting the onset of arteriosclerosis by using a rare sugar D-psicose and a method of inhibiting the onset of arteriosclerosis. | 09-11-2008 |
| 20080221045 | Hepatic Function-Improving Agent - An object of the present invention is to provide a means for improving hepatic function of mammals including humans to normal condition. The present invention achieves the above object by providing a hepatic function-improving agent comprising α-glucosyl-hesperidin as an effective ingredient. | 09-11-2008 |
| 20080221046 | Macrolides With Anti-Inflammatory Activity - The present invention relates to novel semi-synthetic macrolides having anti-inflammatory activity. More particularly, the invention relates to 14- and 15-membered macrolides substituted at the 4″ position, to their pharmaceutically acceptable derivatives, to processes and intermediates for their preparation, to pharmaceutical compositions containing them and to their activity and use in the treatment of inflammatory diseases and conditions in humans and animals, especially those diseases associated with excessive secretion of TNF-α, IL-1, IL-8, IL-2 or IL-5; and/or inhibitor of excessive lymphocyte proliferation; and/or excessive granulocyte degranulation. | 09-11-2008 |
| 20080221047 | Aminoakyl methacrylate copolymer E for maintaining solubility of poorly-soluble drug - A pharmaceutical composition comprising aminoalkyl methacrylate copolymer E, an acidic substance, and a poorly-soluble drug, wherein the aminoalkyl methacrylate copolymer E and the acidic substance are uniformly mixed, and solubility of the poorly-soluble drug is maintained for at least 30 minutes is disclosed. | 09-11-2008 |
| 20080221048 | Lyophilized azithromycin formulation - The invention provides among other things a stable, sterile pharmaceutical formulation comprising lyophilized azithromycin and ethanol. The invention also provides a method of producing a stable, sterile pharmaceutical product comprising lyophilized azithromycin. The invention also provides a pharmaceutical dosage form comprising the pharmaceutical formulation, as well as a method of treating a disease in a patient comprising administering a solution of the pharmaceutical formulation to a patient. | 09-11-2008 |
| 20080221049 | Free-flowing lyophilized tobramycin formulation - The invention provides among other things a stable, sterile pharmaceutical formulation comprising lyophilized tobramycin, wherein the lyophilized tobramycin is in the form of a free-flowing powder. The invention also provides a method of producing a stable, sterile pharmaceutical product comprising lyophilized tobramycin. The invention also provides a pharmaceutical dosage form comprising the pharmaceutical formulation, as well as a method of treating a disease in a patient comprising administering a solution of the pharmaceutical formulation to a patient. | 09-11-2008 |
| 20080221050 | Method for Diagnosing or Predicting Susceptibility to Optic Neuropathy - Disclosed is a set of genetic polymorphisms linked to optic neuropathy including glaucoma and Leber's disease. Those polymorphisms are useful for diagnosing and predicting susceptibility to optic neuropathy. | 09-11-2008 |
| 20080221051 | Formulations comprising antisense nucleotides to connexins - A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation and skin rejuvenation and thickening. | 09-11-2008 |
| 20080221052 | Modulation of Wrn-Mediated Telomere-Initiated Cell Signaling - The use of modulators of WRN is described. Activators of WRN may be used to induce growth arrest, apoptosis or proliferative senescence, whereas inhibitors of WRN may be used to reduce growth arrest, apoptosis or proliferative senescence. Methods of identifying modulators of WRN are also described. | 09-11-2008 |
| 20080221053 | RNA APTAMERS AND METHODS FOR IDENTIFYING THE SAME - RNA aptamers and methods for identifying the same are disclosed. The RNA aptamers selectively bind coagulation factors, E2F family members, Ang1 or Ang2, and therapeutic and other uses for the RNA aptamers are also disclosed. | 09-11-2008 |
| 20080221054 | Inhibiting Gene Expression with dsRNA - The present invention relates to the specific inhibition of gene expression in mammals by bringing the target gene into contact with double stranded RNA (dsRNA). | 09-11-2008 |
| 20080221055 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HUNTINGTIN GENE - The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the HD gene, or a mutant form thereof, using the pharmaceutical composition; and methods for inhibiting the expression of the huntingtin gene in a cell. | 09-11-2008 |
| 20080221056 | Early Detection and Prognosis of Colon Cancers - We have developed a transcriptome-wide approach to identify genes affected by promoter CpG island hypermethylation and transcriptional silencing in colorectal cancer (CRC). By screening cell lines and validating tumor specific hypermethylation in a panel of primary human CRC samples, we estimate that nearly 5% of all known genes may be promoter methylated in an individual tumor. When directly compared to gene mutations, we find a much larger number of genes hypermethylated in individual tumors, and much higher frequency of hypermethylation within individual genes harboring either genetic or epigenetic changes. Thus, to enumerate the full spectrum of alterations in the human cancer genome, and facilitate the most efficacious grouping of tumors to identify cancer biomarkers and tailor therapeutic approaches, both genetic and epigenetic screens should be undertaken. The genes we identified can be used inter alia diagnostically to detect cancer, pre-cancer, and likelihood of developing cancer. | 09-11-2008 |
| 20080221057 | SECRETED PROTEIN CCDC80 REGULATES ADIPOCYTE DIFFERENTIATION - Disclosed herein are methods of modulating adipogenesis. The methods include contacting a cell expressing the Ccdc80 gene with an agent that modulates the expression or activity of the Ccdc80 gene or Ccdc80 protein. Further disclosed herein are methods of treating conditions such as obesity, insulin resistance, and/or type 2 diabetes with Ccdc80 modulators. Also disclosed herein are methods of identifying Ccdc80 modulators. | 09-11-2008 |
| 20080221058 | Tumor-Specific Vector for Gene Therapy - The invention relates to a vector for the gene therapeutic treatment of tumors, especially in connection with radiotherapy. Said vector is provided with a therapeutic gene in the DNA sequence thereof. The gene is controlled by the promoter for the catalytic subunit of the telomerase or by the promoter for cyclin A. | 09-11-2008 |
| 20080221059 | NOVEL TREATMENT TOOL FOR CANCER: RNA INTERFERENCE OF BCAS2 - The present invention provides three BCAS2 related nucleotide sequences. The present invention also provides a composition comprising a nucleotide sequence of small interfering RNA of BCAS2 gene. The present invention further provides a method for treating p53 containing cancer comprising administrating a subject with an effective amount of the said composition. | 09-11-2008 |
| 20080221060 | Therapeutic Compounds - Use of compounds of general formula (A) as medicaments is described, in particular for the treatment of pain or inflammation; wherein: (I) when X=OH, R | 09-11-2008 |
| 20080221061 | Lung-Targeted Drugs - Methods and compositions are provided for treating lung diseases, including but not limited to infections and small cell and non-small cell lung cancer, by conjugating a drug of interest to glycerol ethers or glycerol phosphate ethers. | 09-11-2008 |
| 20080221062 | Hyaluronic Acid Derivative and Drug Containing the Same - A hyaluronic acid derivative in which an anti-inflammatory drug is bound to hyaluronic acid through a covalent bond via a spacer having a biodegradable region, and a production process thereof. | 09-11-2008 |
| 20080221063 | Heterocyclic Sulfonamide Derivatives As Inhibitors Of Factor Xa - The invention relates to heterocyclic derivatives of formula (I), Chemical formula should be inserted here. Please see paper copy wherein R | 09-11-2008 |
| 20080221064 | Medicinal composition for ophthal use containing acetylated hyaluronic acid - The present invention provides an ophthalmic pharmaceutical composition containing acetylated hyaluronic acid and a pharmacologically acceptable carrier. Preferably, the average molecular weight of the acetylated hyaluronic acid is 10,000 to 1,000,000, and the acetyl group substitution number is from 2.0 to 4.0. In a preferred embodiment, this ophthalmic pharmaceutical composition is used in the treatment or prevention of dry eye, and in an even more preferred embodiment it is a dry-eye instillation. | 09-11-2008 |
| 20080221065 | ORGANIC COMPOUNDS - Pharmaceutical formulations comprising an epothilone in the form of an infusion concentrate or a lyophilised composition, and methods of administration of an epothilone in suitable form for parenteral administration. | 09-11-2008 |
| 20080221066 | MODIFIED HYDROXYPOLYMER CONJUGATES WITH KILLING EFFECT ON TUMOR CELLS - The present invention is related to a modified hydroxypolymer conjugates preferably a guanidine-dextran conjugate having a tumor cell killing activity. The modified hydroxypolymer conjugate is used as medicine, particularly for manufacturing a medicine or tumor killing composition for treating tumors. A method for producing said hydroxypolymer conjugate and a method for killing cancer cells and treating tumors is also disclosed. The invention is also related to a method for killing tumor cells and treating tumors by administering an effective amount of the modified hydroxypolymer conjugate. | 09-11-2008 |
| 20080221067 | Wood preservative composition - A wood preservative composition comprising a mixture of a fungicide which is a combination of a boric acid ester, which is soluble in an organic solvent and has a sterically hindered di-alcohol or tri-alcohol group, such as trihexylene glycol biborate, an organo-iodine compound, a triazole, and a synthetic pyrethroid insecticide, said fungicide and the insecticide being present in a sufficient amount that wood treated with the wood treatment material contains fungicide and insecticide in an amount of about 1 ppm to 5000 ppm, based on the weight of the wood after treatment. | 09-11-2008 |
| 20080221068 | ANTI-TUMOR AGENTS - A method for treating subjects with abnormal cell proliferation is provided. The method involves administering to subjects in need of such treatment an effective amount of an agent of Formula I, to inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for inhibiting angiogenesis in an abnormal proliferative cell mass by the administration of an agent of Formula I is also provided. | 09-11-2008 |
| 20080221069 | Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders - The present invention is directed to novel compounds according to formula (I) wherein R | 09-11-2008 |
| 20080221070 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH - Bone targeted compounds and methods are provided. Compounds can include a Bone Targeting Portion (R | 09-11-2008 |
| 20080221071 | Compositions for providing vitamin D year round and uses thereof - Methods for enhancing the ability of an individual, exposed to sunlight, to produce vitamin D via the skin. Pharmaceutical compositions comprising provitamin D and at least one of lumisterol and tachysterol and analogs and derivatives thereof are also disclosed. | 09-11-2008 |
| 20080221072 | Fatty Acid Modified Forms of Glucocorticoids - Compounds are disclosed of the formula | 09-11-2008 |
| 20080221073 | Nitrooxy Derivatives of Glucocorticoids - The invention relates to new steroids nitrooxyderivatives, to topical pharmaceutical formulations thereof, and their use for treating skin or mucosal membrane diseases or disorders. These new steroids nitrooxyderivatives have an improved pharmacological activity and enhanced local tolerability. | 09-11-2008 |
| 20080221074 | Drug Screen and Treatment Method - The invention relates to methods identify or characterize compounds that can be used to treat specified clinical disorders such as hyperglycemia and type 2 diabetes. Compounds that can be used in these methods include 4α-fluoro-17α-ethynylandrost-5-ene-3β,7β,17β-triol, 4α-fluoro-17α-ethynylandrost-5-ene-3β,7α,17β-triol, 4α-fluoro-17α-ethynylandrost-5-ene-3α,7β,17β-triol and 4α-fluoro-17α-ethynylandrost-5-ene-3β,17β-triol-7-one. | 09-11-2008 |
| 20080221075 | Therapeutic Uses For Aminosterol Compounds - A pharmaceutical composition includes, as an active ingredient, a compound according to formula 1436 as shown in FIG. | 09-11-2008 |
| 20080221076 | Crystalline Sodium Salt of Cephalosporin Antibiotic - The present invention relates to novel polymorph of Ceftiofur sodium as a crystalline product. The present invention also provides a process for the preparation of crystalline Ceftiofur sodium of formula (I). | 09-11-2008 |
| 20080221077 | Ansamycin formulations and methods of use thereof - Provided herein, inter alia, are solid forms of geldanamycin analogs, pharmaceutical compositions comprising a geldanamycin analog and a crystallization inhibitor, methods of making and using such compositions. Additionally, provided are methods for the treatment of cancer, a neoplastic disease state and/or a hyperproliferative disorder, and methods of inhibiting Heat Shock Protein 90 (“Hsp90”). | 09-11-2008 |
| 20080221078 | Use of a CB1 Antagonist for Treating Side Effects and Negative Symptoms of Schizophrenia - The present invention discloses and claims a method of treating cognition deficits in a patient suffering from schizophrenia by administering to said patient a therapeutically effective amount of a CB1 receptor antagonist as described herein. In another aspect, this invention also discloses and claims a combination of one or more CB1 receptor antagonists and of one or more antipsychotic agents useful in the treatment of psychiatric disorders. The combination of this invention provides synergistic results in that the combination improves positive and negative symptoms of schizophrenia, weight gain and catalepsy. | 09-11-2008 |
| 20080221079 | PHARMACEUTICAL COMPOSITION OF QUETIAPINE FUMARATE - A pharmaceutical composition comprising (i) quetiapine or a pharmaceutically acceptable salt thereof, especially quetiapine fumarate; (ii) a mixed excipient comprising an intimate admixture of polyvinylacetate and polyvinylpyrrolidone in a weight ratio from 5:2 to 10:2; and, optionally (iii) an acid especially fumaric acid. | 09-11-2008 |
| 20080221080 | Method of Treating Mixed Lineage Leukemia Gene-Rearranged Acute Lymphoblastic Leukemias - The present invention relates to a method of treating a warm-blooded animal, especially a human, having Mixed Lineage Leukemia (MLL rearranged ALL) comprising administering to said animal a therapeutically effective amount of a staurosporine derivative, especially PKC412 or a pharmaceutically acceptable salt thereof, alone or in combination with further therapeutic measures, for example, those defined herein; to the use of a staurosporine derivative for the preparation of a medicament for the treatment of MLL rearranged ALL; and to a commercial package comprising a staurosporine derivative together with instructions for its use in the treatment of MLL rearranged ALL. | 09-11-2008 |
| 20080221081 | POLYMORPHS OF 7-[(3-CHLORO-6,11-DIHYDRO-6-METHYLDIBENZO[C,F][1,2]THIAZEPIN-11-YL)AMINO]HEPTANOIC ACID S,S DIOXIDE AND METHODS OF MAKING AND USING THE SAME - Disclosed herein are novel polymorphs of 7-[(3-chloro-6,11-dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide. Also described herein are novel pharmaceutical compositions comprising one or more 7-[(3 chloro-6,11-dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide polymorphs, methods of making, and related methods of treatment. | 09-11-2008 |
| 20080221082 | Ligands of Integrin Receptors - The invention relates to the use of cyclic compounds as ligands of integrin receptors, in particular as ligands of the α | 09-11-2008 |
| 20080221083 | Heterobicyclic metalloprotease inhibitors - The present invention relates generally to amide containing heterobicyclic containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-3 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13 and MMP-3 inhibitors. | 09-11-2008 |
| 20080221084 | METHOD FOR REDUCING INFARCTION USING VASOPRESSIN ANTAGONIST COMPOUNDS, AND COMPOSITIONS AND COMBINATIONS THEREFOR - The present invention relates to a method for reducing infarction comprising administering to a patient ion need thereof a therapeutically effective amount of a composition comprising as an active ingredient a vasopressin antagonist compound and to a composition useful therefor. The present invention also relates to a method for reducing infarction comprising administering to a patient in need thereof a therapeutically effective amount of a combination of a vasopressin antagonist compound and a beta-blocker and to combinations useful therefor. The methods, compositions and combinations of the present invention can be used for reducing infarction in the heart (myocardial infarction) and the brain (stroke). The methods, compositions and combinations of the present invention can also be used for the treatment and/or prevention of hypertension, edema, ascites, heart failure, renal function disorder, vasopressin inappropriate secretion syndrome (SIADH), hepatocirrhosis, hyponatremia, hypokalemia, polycystic kidney disease, diabetes, or circulation disorder. | 09-11-2008 |
| 20080221085 | Nicotinic Receptor Agonists for the Treatment of Inflammatory Diseases - Nicotine receptor agonists or analogs or derivatives thereof for treating inflammatory pulmonary diseases, and pharmaceutical compositions including nicotine receptor agonists or analogs or derivatives thereof. Compounds of formula wherein R1, R2, Xa and Ya are as defined herein are also provided. | 09-11-2008 |
| 20080221086 | Novel Inhibitors of Glutaminyl Cyclase - The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy, | 09-11-2008 |
| 20080221087 | Substituted lactams as inhibitors of abeta protein production - This invention relates to novel lactams of Formula (I): | 09-11-2008 |
| 20080221088 | 3,4-Substituted Thiazoles as Ampk Activators - The present application provides novel thiazole derivatives that are useful as activators of Adenosine 5′-Monophosphate-Activated Protein Kinase and pharmaceutical compositions containing such compounds. | 09-11-2008 |
| 20080221089 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY - The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful. | 09-11-2008 |
| 20080221090 | HCV NS5B Inhibitors - The invention encompasses compounds of Formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV. | 09-11-2008 |
| 20080221091 | Metalloprotease inhibitors containing a heterocyclic moiety - The present invention relates generally to pharmaceutical agents containing a heterocyclic moiety, and in particular, to heterocyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterocyclic MMP-13 inhibiting compounds with a modified benzoxazine moiety, that exhibit an increased potency and selectivity in relation to currently known MMP-13 inhibitors. | 09-11-2008 |
| 20080221092 | Heterobicyclic metalloprotease inhibitors - The present invention relates generally to amide containing heterobicyclic containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-3 and/or MMP-13 inhibiting compounds that exhibit an increased potency and selectivity in relation to currently known MMP-13 and MMP-3 inhibitors. | 09-11-2008 |
| 20080221093 | Metalloprotease inhibitors containing a heterocyclic moiety - The present invention relates generally to pharmaceutical agents containing a heterocyclic moiety, and in particular, to heterocyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterocyclic MMP-13 inhibiting compounds with a benzoxazinone moiety, that exhibit an increased potency and selectivity in relation to currently known MMP-13 inhibitors. | 09-11-2008 |
| 20080221094 | Metalloprotease inhibitors containing a squaramide moiety - The present invention relates generally to pharmaceutical agents containing a heterocyclic moiety, and in particular, to heterocyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterocyclic MMP-13 inhibiting compounds with a squaramide moiety, that exhibit an increased potency and selectivity in relation to currently known MMP-13 inhibitors. | 09-11-2008 |
| 20080221095 | Metalloprotease inhibitors containing a heterocyclic moiety - The present invention relates generally to pharmaceutical agents containing a heterocyclic moiety, and in particular, to heterocyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterocyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds with a squaramide or benzoxazinone moiety, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors. | 09-11-2008 |
| 20080221096 | Pyrido[3' ,2':4,5]Furo[3,2-d]Pyrimidine Derivatives - The present disclosure relates to a pyridofuropyrimidine derivative of formula (I): | 09-11-2008 |
| 20080221097 | Imidazopyridine Derivatives as Cannabinoid Receptor Ligands - The present invention relates to novel imidazopyridine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor. | 09-11-2008 |
| 20080221098 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS - The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, Bmx, c-Raf, Csk, Fes, FGFR, Flt3, Ikk, IR, JNK, Lck, Mkk, PKC, PKD, Rsk, SAPK, Syk, Trk, BTK, Src, EGFR, IGF, Mek, Ros and Tie2 kinases. | 09-11-2008 |
| 20080221099 | DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES - Disclosed is the use of a compound of general Formula (1), | 09-11-2008 |
| 20080221100 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS - Disclosed are urea compounds, stereoisomer, or pharmaceutical acceptable salt thereof, and compositions that inhibit soluble epoxide hydrolase (sEH), methods for preparing the compounds and compositions, and methods for treating patients with such compounds and compositions. The compounds, compositions, and methods are useful for treating a variety of sEH mediated diseases, including hypertensive, cardiovascular, inflammatory, pulmonary, and diabetic-related diseases. | 09-11-2008 |
| 20080221101 | Calcium receptor modulating agents - The present invention relates generally to compounds represented in Formula I, pharmaceutical compositions comprising them and methods of treating of diseases or disorders related to the function of the calcium sensing receptor. The invention also relates to processes for making such compounds and to intermediates useful in these processes. | 09-11-2008 |
